Optimising urinary catecholamine metabolite diagnostics for neuroblastoma
(2023) In Pediatric Blood and Cancer 70(6).- Abstract
Introduction: The analysis of urinary catecholamine metabolites is a cornerstone of neuroblastoma diagnostics. Currently, there is no consensus regarding the sampling method, and variable combinations of catecholamine metabolites are being used. We investigated if spot urine samples can be reliably used for analysis of a panel of catecholamine metabolites for the diagnosis of neuroblastoma. Methods: Twenty-four-hour urine or spot urine samples were collected from patients with and without neuroblastoma at diagnosis. Homovanillic acid (HVA), vanillylmandelic acid (VMA), dopamine, 3-methoxytyramine, norepinephrine, normetanephrine, epinephrine and metanephrine were measured by high-performance liquid chromatography coupled with... (More)
Introduction: The analysis of urinary catecholamine metabolites is a cornerstone of neuroblastoma diagnostics. Currently, there is no consensus regarding the sampling method, and variable combinations of catecholamine metabolites are being used. We investigated if spot urine samples can be reliably used for analysis of a panel of catecholamine metabolites for the diagnosis of neuroblastoma. Methods: Twenty-four-hour urine or spot urine samples were collected from patients with and without neuroblastoma at diagnosis. Homovanillic acid (HVA), vanillylmandelic acid (VMA), dopamine, 3-methoxytyramine, norepinephrine, normetanephrine, epinephrine and metanephrine were measured by high-performance liquid chromatography coupled with fluorescence detection (HPLC-FD) and/or ultra-performance liquid chromatography coupled with electrospray tandem mass spectrometry (UPLC-MS/MS). Results: Catecholamine metabolite levels were measured in urine samples of 400 neuroblastoma patients (24-hour urine, n = 234; spot urine, n = 166) and 571 controls (all spot urine). Excretion levels of catecholamine metabolites and the diagnostic sensitivity for each metabolite were similar in 24-hour urine and spot urine samples (p >.08 and >.27 for all metabolites). The area under the receiver-operating-characteristic curve (AUC) of the panel containing all eight catecholamine metabolites was significantly higher compared to that of only HVA and VMA (AUC = 0.952 vs. 0.920, p =.02). No differences were observed in metabolite levels between the two analysis methods. Conclusion: Catecholamine metabolites in spot urine and 24-hour urine resulted in similar diagnostic sensitivities. The Catecholamine Working Group recommends the implementation of spot urine as standard of care. The panel of eight catecholamine metabolites has superior diagnostic accuracy over VMA and HVA.
(Less)
- author
- contributor
- Øra, Ingrid LU
- author collaboration
- publishing date
- 2023-06
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- catecholamine metabolites, diagnostic sensitivity, metanephrines, neuroblastoma, tandem mass spectrometry, urine collection
- in
- Pediatric Blood and Cancer
- volume
- 70
- issue
- 6
- article number
- e30289
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:37010353
- scopus:85151655848
- ISSN
- 1545-5009
- DOI
- 10.1002/pbc.30289
- language
- English
- LU publication?
- no
- additional info
- Funding Information: This work was supported by a grant from the Villa Joep Foundation. Publisher Copyright: © 2023 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
- id
- a317148f-234e-4506-a93a-a74230845e83
- date added to LUP
- 2023-12-04 19:08:39
- date last changed
- 2024-04-17 15:19:34
@article{a317148f-234e-4506-a93a-a74230845e83,
abstract = {{<p>Introduction: The analysis of urinary catecholamine metabolites is a cornerstone of neuroblastoma diagnostics. Currently, there is no consensus regarding the sampling method, and variable combinations of catecholamine metabolites are being used. We investigated if spot urine samples can be reliably used for analysis of a panel of catecholamine metabolites for the diagnosis of neuroblastoma. Methods: Twenty-four-hour urine or spot urine samples were collected from patients with and without neuroblastoma at diagnosis. Homovanillic acid (HVA), vanillylmandelic acid (VMA), dopamine, 3-methoxytyramine, norepinephrine, normetanephrine, epinephrine and metanephrine were measured by high-performance liquid chromatography coupled with fluorescence detection (HPLC-FD) and/or ultra-performance liquid chromatography coupled with electrospray tandem mass spectrometry (UPLC-MS/MS). Results: Catecholamine metabolite levels were measured in urine samples of 400 neuroblastoma patients (24-hour urine, n = 234; spot urine, n = 166) and 571 controls (all spot urine). Excretion levels of catecholamine metabolites and the diagnostic sensitivity for each metabolite were similar in 24-hour urine and spot urine samples (p >.08 and >.27 for all metabolites). The area under the receiver-operating-characteristic curve (AUC) of the panel containing all eight catecholamine metabolites was significantly higher compared to that of only HVA and VMA (AUC = 0.952 vs. 0.920, p =.02). No differences were observed in metabolite levels between the two analysis methods. Conclusion: Catecholamine metabolites in spot urine and 24-hour urine resulted in similar diagnostic sensitivities. The Catecholamine Working Group recommends the implementation of spot urine as standard of care. The panel of eight catecholamine metabolites has superior diagnostic accuracy over VMA and HVA.</p>}},
author = {{Matser, Yvette A.H. and Verly, Iedan R.N. and van der Ham, Maria and de Sain-van der Velden, Monique G.M. and Verhoeven-Duif, Nanda M. and Ash, Shifra and Cangemi, Giuliana and Barco, Sebastiano and Popovic, Maja Beck and van Kuilenburg, André B.P. and Tytgat, Godelieve A.M.}},
issn = {{1545-5009}},
keywords = {{catecholamine metabolites; diagnostic sensitivity; metanephrines; neuroblastoma; tandem mass spectrometry; urine collection}},
language = {{eng}},
number = {{6}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Pediatric Blood and Cancer}},
title = {{Optimising urinary catecholamine metabolite diagnostics for neuroblastoma}},
url = {{http://dx.doi.org/10.1002/pbc.30289}},
doi = {{10.1002/pbc.30289}},
volume = {{70}},
year = {{2023}},
}